Education
About Us
Working with TipRanks
Follow Us
Hua Medicine Ltd. (HK:2552)
:2552
2552 Stock Chart & Stats
HK$3.08
-HK$0.05(-3.62%)
At close: 4:00 PM EST
HK$3.08
-HK$0.05(-3.62%)
Day’s Range― - ―
52-Week RangeHK$1.24 - HK$4.95
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.34M
Market Cap
HK$3.00B
Enterprise ValueHK$1.98B
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$271.05M
Price to Earnings (P/E)2.6
Beta1.18
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.30
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-9.93
Price to Sales (P/S)5.26
P/FCF Ratio-3.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$1.24 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$3.00B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 98 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Aug 28, 2025. The company reported HK$1.301 earnings per share for the quarter, beating the consensus estimate of N/A by HK$1.301.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of HK$1.301 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
2552 Company Deck
2552 Earnings Call
Q2 2025
0:00 / 0:00
Technical Analysis
Essex Bio-Technology
―
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
China Shineway Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---